Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

In this RCT (n=435), PASI90 was achieved in 91% of patients receiving the IL-17F and IL-17A inhibitor bimekizumab (320mg every 4 weeks) compared to 1% receiving placebo (p<0.0001), and an IGA score of 0 or 1 was achieved in 93% v 1%, respectively (p<0.0001).

Source:

The Lancet